The combination of COM701 + BMS-986207 + nivolumab demonstrates preliminary anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer. NCT04570839.

Drew W. Rasco,1 Daniel A. Vaena,2 Gini F. Fleming,3 Eaterina Elena Dumbrava,4 Oladapo O. Yeku,5 Manish Sharma,5 Kyriakos P. Papadopoulos,6 Ryan J. Sullivan,1 Stephanie Gaillard,3 Adobeye H. Adewoey,1 Inbal Barbiro,7 Pierre Ferre,10 John William Moroney11

1The START Center for Cancer Care, Tyler, TX; 2Multicenter Clinical Research, Memphis, TN; 3University of Chicago, Chicago, IL; 4Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; 5Department of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 6Voltaje Group S.A., San Francisco, CA; 7Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 8Genentech, South San Francisco, CA; 9Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; 10Histology, Memorial Sloan-Kettering Cancer Center, New York, NY; 11Sloan-Kettering Institute for Cancer Research, New York, NY.

BACKGROUND: COM701 is a novel small molecule transcriptional inhibitor (SMTI) that blocks protein receptor-related transcriptional mediated cancer growth through inhibition of activation of 7α and 9α HSD.

METHODS: In this study we report on 9 patients: 1 patient, 2-7

SUMMARY OF INVESTIGATOR-ASSESSSED RESPONSE [RECIST V1.1]

Parameter

COMBO (vehicle only, n=16) (n=2)

Final activity per tumor site was evaluated per RECIST v1.1 with a CT imaging every 8 weeks starting from the first day of the cycle of the study and every 16 weeks thereafter in case of any time point progressed or disease is suspected.

Study treatment for 2yrs unless PD, toxicity, withdrawal of consent, PI discretion thereafter (or at any time point progressive disease is suspected)

In this study we report on 9 patients:• Comprehensive Cancer Center, Baltimore, MD;• Clinical Development., Compugen USA Inc., San Francisco, CA;• The Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;• University of Chicago, Chicago, IL;• University of Texas MD Anderson Cancer Center, Houston, TX;• University of California San Francisco, San Francisco, CA;• University of Texas MD Anderson Cancer Center, Houston, TX;• Sloan-Kettering Institute for Cancer Research, New York, NY;• Memorial Sloan Kettering Cancer Center, New York, NY;• Gigi F. Fleming, et al., SITC 2021

CONCLUSIONS: The triplet combination of COM701 with nivolumab and BMS-986207 is well tolerated and has a favorable safety and toxicity profile with no new safety signal.

The triplet combination demonstrates encouraging preliminary signal of antitumor activity in patients with metastable recurrent, metastatic endometrial cancer:

- Confirmed partial response in 2/9 (ORR 22%) patients.
- The triplet combination demonstrates encouraging preliminary signal of anti-tumor activity in pts with microsatellite stable recurrent, metastatic endometrial cancer (1) ± BMS-986207 + nivolumab.
- The triplet combination of COM701 with nivolumab and BMS-986207 is well tolerated and has a favorable safety and toxicity profile with no new safety signal.

- Confirmed partial response in 2/9 (ORR 22%) patients.

- The combination of COM701 with nivolumab and BMS-986207 is well tolerated and has a favorable safety and toxicity profile with no new safety signal.

- The triplet combination demonstrates encouraging preliminary signal of antitumor activity in patients with metastable recurrent, metastatic endometrial cancer:

- Confirmed partial response in 2/9 (ORR 22%) patients.